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Hepatitis C virus has a genetically determined
lymphotropism through co-receptor B7.2
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B-cell infection by hepatitis C virus (HCV) has been a controversial topic. To examine whether
HCV has a genetically determined lymphotropism through a co-receptor specific for the
infection by lymphotropic HCV, we established an infectious clone and chimeric virus of
hepatotropic and lymphotropic HCV strains derived from an HCV-positive B-cell lymphoma.
The viral envelope and 50-UTR sequences of the lymphotropic HCV strain were responsible
for the lymphotropism. Silencing of the virus sensor, RIGI, or overexpression of microRNA-122
promoted persistent viral replication in B cells. By cDNA library screening, we identified an
immune cell-specific, co-stimulatory receptor B7.2 (CD86) as a co-receptor of lymphotropic
HCV. Infection of B cells by HCV inhibited the recall reaction to antigen stimulation. Together,
a co-receptor B7.2 enabled lymphotropic HCV to infect memory B cells, leading to inhibition
of memory B-cell function and persistent HCV infection in HCV-infected hosts.
DOI: 10.1038/ncomms13882 OPEN
1 Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, 2011 Zonal Avenue, Los Angeles,
California 90033, USA. 2Department of Cell and Neurobiology, Keck School of Medicine, University of Southern California, 2011 Zonal Avenue, Los Angeles,
California 90033, USA. 3 Department of Microbiology and Immunology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill,
Chapel Hill, North Carolina 27599-7290, USA. 4 Institute of Molecular Biology, Academia Sinica, Taipei 115, Taiwan. 5 Department of Virology II, National
Institute of Infectious Diseases, Tokyo 162-8640, Japan. 6 International Center for Infectiology Research, Team EVIR, Inserm, U1111, Universite´ Claude Bernard
Lyon 1, CNRS, UMR5308, Ecole Normale Supe´rieure de Lyon, Univ Lyon, F-69007 Lyon, France. Correspondence and requests for materials should be
addressed to K.M. (email: keigo.machida@med.usc.edu).
NATURE COMMUNICATIONS | 8:13882 |DOI: 10.1038/ncomms13882 | www.nature.com/naturecommunications 1
H
epatitis C virus (HCV) infection often persists despite
robust host immune responses, consequently leading to
chronic hepatitis, liver cirrhosis and hepatocellular
carcinoma. However, HCV infection and replication in immune
cells remains controversial and is not universally accepted. Even
though experimental and clinical evidence accumulated during
the last two decades are compelling, the issue remains
controversial mainly due to insufficient information and deeply
fragmented knowledge. Another potentially serious complication
of HCV infection is the possible infection of peripheral blood
mononuclear cells (PBMC) by HCV leading to B-lymphocyte
proliferative disorders, including mixed cryoglobulinemia,
oligoclonal proliferation of B cells1,2, and B-cell non-Hodgkin’s
lymphoma2–5. Still, HCV infection of B cells and its possible
association with B-cell disorders remains a controversial
subject6,7.
It was reported from McKeating’s group that HCV replication
in lymphocytes is relatively rare and attachment of HCV particles
to B lymphocytes did not lead to productive HCV replication7.
HCV promoted the adhesion of primary B cells to Huh-7 cells for
retention of B cells on infected hepatocytes, thus implying that
B cells may provide a vehicle for HCV persistence by
transmission to the liver. Additionally, lymphotropism of HCV
(SB strain: patient splenoma B-cell-derived isolated by our group)
is not limited to B cells since we have identified HCV infection
(SB strain) of T cells and subsequent alterations in their
functions8,9. These studies, however, did not provide conclusive
evidence that other molecules on other immune cell types serve as
HCV co-receptors.
Cellular surface receptors have been identified as
factors promoting viral tropism. HCV uses cell surface factors
(LDL-R and HSPG) (ref. 10) for attachment and additional entry
factors for infection of hepatocytes. The entry factors include the
Scavenger Receptor class B type I (SRB1 or SR-BI) (ref. 11), the
tetraspanin CD81 (ref. 12), the tight junction proteins CLDN1
(ref. 13) and the receptor tyrosine kinases EGFR and EphA2
(ref. 14). More recently, the Niemann-Pick C1-like 1 (NPC1L1)
cholesterol absorption receptor and the iron uptake receptor
transferrin receptor 1 (TfR1) have also been shown to play a
role in HCV entry15. Among these, four co-receptors (Claudin-1,
Occludin, CD81 and SR-BI) are potentially involved in HCV
entry12,16–18, while sulfated homologues of heparin inhibit HCV
entry into mammalian cells19. These co-receptors are associated
with the viral envelope glycoprotein of HCV. The viral envelope
proteins include E1 and E2, which assemble as heterodimers in
the prebudding virion form20.
Mutations in the 50-UTR (50-untranslated region) of a
hepatotropic HCV strain (H77) cultured in T lymphoid cell lines
enhanced viral replication specifically in T lymphoid cells
(MOLT-4) (ref. 21). The presence of different, strain-specific
50-UTR sequences or sequence heterogeneities in the region
coding for E1 or E2 can result in altered lymphotropism when
compared to hepatotropic strains22,23. However, the
lymphotropism of these viruses and the significance of these
sequence variations were not fully established since only three
nucleotide substitutions found in the 50-UTR in hepatotropic
JFH1 strain and variant H77 strain passaged in lymphocytes are
unchanged. The sequence variations in the 50-UTR region are
usually associated with B and T lymphocyte replication of HCV
(refs 21,24,25). It has been shown that the B-cell specific 50-UTR
has a lower translation difference observed between lymphotropic
and hepatotropic strains26. (The lymphotropic strain may have a
less efficient 50-UTR for translation).
The viral envelope protein is frequently mutated in chronically
infected subjects, whereas the 50-UTR of HCV RNA in B cells is
not frequently mutated22, suggesting that B cells suppress
replication of less competent viral sequences whereas liver cells
are not as stringent. In SCID mice inoculated with experimentally
mutated HCV strains, the HCV mutations in the 50-UTR
(specifically the IRES) or C-E1-E2 regions have different
consequences on genome replication and/or translational
activity as a function of cell type26,27. Moreover, the 30-UTR
also contributes to efficient RNA replication of HCV (ref. 28).
The 30-end of the NS5B-coding region has been shown to form
part of a secondary structure (kissing loop) involving the 30-UTR
(ref. 28). This fact may explain why the HCV pseudoparticle
(HCVpp) bearing HCV envelope alone did not confer robust
replication ability in B cells.
MicroRNA-122 (miR-122) is the most abundant miRNA
species in liver and binds the 50-UTR of HCV genomic RNA to
facilitate HCV replication. Chronic liver damage results in release
of miR-122 into the blood stream and exposes miR-122 to
immune cells. However, the role of miR-122 for HCV replication
in immune cells is not documented. MicroRNA-122 is not only
expressed in the liver but also in malignant and chemotherapy-
treated lymphocytes29,30, and positively regulates HCV
replication in hepatocytes31–33. Circulating miR-122 can be
taken up by several cell types, including lymphocytes34,35
thereby facilitating HCV replication. We hypothesized that this
uptake of miR-122 facilitates HCV replication in B cells. Indeed,
circulating plasma miR-122 in exosomes is elevated in early stage
fibrosis induced by various aetiologies, including HCV infection,
hepatocyte injury and inflammation36–39.
In this study, we hypothesized that the ability of certain HCV
strains to infect B cells was determined by the sequence variation
of the viral genome. We used genetic approaches to show that
different HCV strains vary in their relative lymphotropism or
hepatotropism. The B-cell infection by lymphotropic HCV may
play a role in HCV pathogenesis. These results are crucial for
studying the natural history of HCV infections in order to gauge
the full scope of its subsequent pathological consequences
resulting from HCV infections. We investigated the roles of
plasma miR-122 in HCV pathogenesis, especially in lympho-
cytes31 and the role of exosome-mediated delivery of tropic
factors in creating a permissive environment for viral infection
and replication.
Results
Lymphotropic SB-HCV strain encodes a unique E1-E2.
We have previously isolated an HCV clone (SB-HCV) from an
HCV-infected (þ ) B-cell lymphoma line40. This virus variant
can infect B cells in vitro40; however, virus production was low for
reasons unclear. To answer this question we used a genetic
approach and assembled the full-length SB viral genomic RNA
(genotype 2b) cloned from HCV infected SB cells40. Viral RNA
was cloned in 14 overlapping cDNA fragments using primer sets
based on the consensus sequences (Supplementary Fig. 1).
Sequence determination of the resulting full-length, HCV
cDNA showed that the SB-HCV strain represented a unique
HCV isolate.
To determine whether unrelated HCV strains replicate to
differing extents in B cells, we compared the full-length RNAs
from the SB and JFH-1 strains, the latter of which is a well-
established hepatotropic strain41, by in vitro transfection of either
Huh7.5.1 cells (a hepatocellular carcinoma cell line with
inactivating mutations in RIG-I) or Raji cells (a human
B-lymphoid cell line) (Fig. 1). In Raji cells, the SB viral RNA
titer remained at 104-105 copies mg 1 of RNA at day 20 post-
transfection. For the corresponding RNA polymerase active site
(GND) mutant RNA, which contains an inactivating mutation of
NS5B (replication incompetent virus) (Fig. 1a), viral RNA
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decreased over three weeks of incubation. By comparison,
the RNA titer of the JFH-1 strain quickly declined in Raji
cells. These results indicated that the SB-HCV strain, but not the
JFH-1 strain, was able to replicate or was unstable RNA in Raji
cells. Conversely, in Huh7.5.1 cells (Fig. 1c), the SB-HCV strain
was less efficiently replicated by day 28 post-transfection when
compared to Raji cells (Fig. 1a); this indicated that Raji cells are
more permissive for SB strain replication than Huh7.5.1. cells.
During the chronic HCV infection stage, the RIGI RNA sensor
pathway is impaired because HCV protease NS3/4A cleaves the
RIGI adaptor protein MAVS (IPS-1) (refs 42,43). Furthermore,
chronic inflammatory cytokines induce negative feedback
pathways through induction of NLRX1 (refs 44,45) to moderate
the excessive activation of RIGI pathways. To study how HCV
interacts with B cells, Raji cells were infected with a lentiviral
vector expressing shRNA targeting RIGI to reduce the antiviral
defences (Fig. 1b). Indeed, silencing RIGI in Raji cells significantly
increased HCV RNA levels and reduced interferon (IFN)-b
induction probably due to defective viral RNA recognition and
induction of RIGI downstream genes (that is, IFN-b). In contrast,
silencing of MDA5, another innate immune receptor, did not
have any further effect (Supplementary Fig. 2), which was
consistent with the finding that HCV RNA binds to RIGI, but not
to MDA5 (ref. 46). The highly permissive hepatotropic liver cell
line (Huh7.5.1), which is highly permissive for hepatotropic
HCV, has an amino acid replacement (T55I) in the first CARD-
homology domain47 of RIGI, resulting in inactivation of RIGI
function. Therefore, the tropism of HCV-SB and hepatotropic
strains was compared under identical RIGI-deficient conditions
(Fig. 1b,c).
To identify the viral gene or genome region(s) responsible for
the differential cellular tropism of these viral strains,
we constructed chimeric virus genomes from the lymphotropic
SB-HCV and hepatotropic JFH-1 HCV strains (Fig. 1d). These
constructs were then converted into full-length infectious RNA
for transfection into recipient cells (Fig. 1d). From the results of
the various viral genome chimeras, it was apparent that all
chimeric genomes containing the SB 50-UTR and homologous
structural proteins replicated well in sh-RIGI-Raji cells and
released viral RNA (some of them are associated with virion) into
the cell culture supernatant. In particular, a chimera containing
the JFH1 backbone and the entire SB 50-UTR-Core-E1-E2-
p7-NS2 (construct F: at the second transmembrane domain
of NS2) replicated 50-fold more robustly than the parental
SB virus in sh-RIGI-Raji cells, producing nearly 107 HCV
RNA copiesml 1. By contrast replication-incompetent
SB/JFH1 GND mutant virus RNA levels were significantly lower
(construct G). The corresponding reciprocal genome constructs
containing E1-E2 and the 50-UTR from JFH1 (construct E)
replicated poorly in sh-RIGI-Raji cells. In Huh7.5.1 cells,
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Figure 1 | Genetic determinants of tissue tropism of HCV SB and JFH1 viruses. (a–c) HCV virus RNA in the parental Raji cells (a), RIG-I knockdown Raji
(sh-RIGI-Raji) cells (b) or Huh7.5.1 cells (c). Cells were harvested from day 1 until day 28 after HCV RNA transfection. The HCV RNA titers were
determined by qRT-PCR (performed in quadruplicates, n¼ 3). Error bars represent s.d. (d) Genetic structure of virus chimera assembled from the SB and
JFH-1 strains. The chimeric viruses were transfected into Raji (sh-RIGI-Raji) or Huh7.5.1 cells as indicated; cellular HCV RNA was quantitated by qRT-PCR at
24 days after transfection (Left and Right). The HCV RNA titers in the supernatant are shown in (d, middle). HCV SB, but not commonly studied JFH-1
strain, preferentially infects, replicates and produces virion particles in sh-RIGI-Raji lymphoma B cells, but not in Huh7.5 hepatocyte cells (n¼ 3). Error bars
represent s.d.
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this result was reversed: JFH-1 RNA replicated to a level of
107 RNA copiesml 1, whereas SB RNA replication was
decreased to a significantly lower level (Po0.05, t-test).
Furthermore, mutations in the 50-UTR regions of SB and JFH1
strains (constructs L and M) resulted in significantly reduced
HCV RNA levels in lymphocytes. These results suggested that
there are distinct hepatotropic and lymphotropic HCV strains,
whose tropism is largely determined by the envelope proteins
(E1-E2) and their respective 50-UTRs. This dramatic increase
was probably due to the sequence changes that occurred at a
crucial junction between the second transmembrane segments of
NS2 as previously suggested48.
To further ascertain the importance of E1-E2 proteins in
the lymphotropism of SB virus, we produced HCVpp using
an envelope-defective HIV-1 proviral vector49–51. This HCVpp
bears the E1 and E2 envelope proteins of HCV and contains a
luciferase reporter gene in the lentivector. As shown in Fig. 2a,
HCVpp bearing the SB E1-E2 envelope proteins could efficiently
infect Raji cells, whereas its infectivity of Huh7.5.1 cells was
significantly lower. As a control, HCVpp assembled with either
E1 or E2 proteins alone were not infectious. The infectivity
of HCVpp with SB envelope protein in Raji cells was substantially
lower (more than 3-logs lower) than that of HIV vector
pseudotyped with MLV Env. Addition of neutralizing anti-E2
antibody (CBH5 clone) specifically antagonized HCVpp
entry into Raji cells (Fig. 2a, right). The ability of HCVpp-SB to
infect Raji cells gives further support that the SB strain is
lymphotropic while HCVpp-JFH1 do not infect Raji cells. Indeed,
in the CD81-interacting domain of the E2 region52–54, the
SB-HCV amino acid sequence is homologous to other HCV
strains, but does have several unique residues that may be
responsible for the observed lymphotropism (Fig. 2c). Another
genotype 2b strain (AB 30907) has the highest homology to the
SB strain among all HCV genotypes while the H77 genotype
1 strain has lesser homology with the SB strain (Fig. 2b,c). Amino
acids G496 and N514 of SB HCV E2 are unique amino acids in
comparison to other HCV E2 sequences, which contain S514
(ref. 55). The G496C substitution has been shown to form a
disulfide bond with C567 (ref. 55). Substitution of G496 by
Cys significantly reduced SB E2 binding to B cells while this
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substitution significantly increased virus entry into Huh7
cells (Fig. 2d). Formation of the disulfide bonding between
G496C and C567 may restore or stabilize a conformation
favourable of E2 for entry into hepatocyte HCV co-receptors
(Fig. 2d). These results confirmed that the E1-E2 envelope
proteins conferred the observed lymphotropism exhibited by
the SB strain in addition to the properties of strain-specific
50-UTRs.
Envelope and 50-UTR determine lymphotropism of SB virus.
The predicted secondary structure of the SB 50 UTR includes
several possible RNA stem-loop structures (Fig. 3a).
Five nucleotide differences between the SB and JFH1 strains are
found within 50-UTR and their positions are indicated (Fig. 3a).
To address the significance of these genetic differences, and
potential effects on RNA secondary structure, four out of five
nucleotides were changed from the SB strain to those found in
the JFH1 strain. Interestingly, the four-nucleotide substitutions
significantly reduced HCV RNA levels in sh-RIGI-Raji cells at
20 days post transfection of HCV RNA (Fig. 3b). The A181G
and U280C substitutions did not affect HCV RNA levels, but
combined substitutions (A181G, U256G, C276A and U280C),
and to a lesser extent, U256G and C276A substitutions reduced
HCV RNA levels. However, it cannot be excluded that these
differences may be due to changes in RNA stability. Therefore,
we constructed a mutant subgenomic JFH1 replicon to see if
substitutions of the 50-UTR sequence promoted replication in B
cells. The 50-UTR sequences were replaced with SB
50-UTR sequences of the JFH1 subgenomic HCV replicon.
We observed that combined substitutions in G181A, G256U,
A276C and C280U increased HCV RNA levels of the JFH1
subgenomic replicon (Fig. 3c) in sh-RIGI-Raji cells. These
results indicated that nucleotides A181, U256, C276 and U280 of
the 50-UTR have key roles in regulating HCV levels in sh-RIGI-
Raji cells.
To prove that SB-HCV recombinants produced infectious
virus particles, the culture supernatant from the transfected
cells was used to infect naı¨ve sh-RIGI-Raji or Huh7.5.1 cells by
using a batch system to ensure a cell-free transfer (Supplementary
Fig. 3). SB RNA-transfected Raji cells produced infectious virus
that infected naı¨ve sh-RIGI-Raji cells (Supplementary Fig. 3A and
B), but was less efficient at replication in Huh7.5.1 cells
(Supplementary Fig. 3C). The converse was true for the JFH
strain in Huh7.5.1 cells (Supplementary Fig. 3C). Infectivity of
SB/JFH1 virus was directly quantified by limiting dilution assay,
demonstrating that HCV-infected cells have infectivity of 40%
(6/15 clones) at day 13 and 38% (6/16 clones) at day
20 (Supplementary Fig. 3D). Infection of HCV did not
significantly affect cell proliferation (Supplementary Fig. 3E).
The role of miR-122 in HCV lymphocyte infection
was examined by transduction of miR-122 into B lymphocytes.
A miR-122 expressing lentivirus was transduced into sh-RIGI-
Raji cells and cells were challenged with HCV (Fig. 3d).
The results showed that miR-122 transduction signi-
ficantly enhanced HCV replication, producing virus titers of
2 106 copiesml 1 and 108 copiesmg 1 of cellular RNA
(387-fold increase: Po0.001, t-test) after 3 weeks post-transduc-
tion (Fig. 3e). Cellular miR-122 levels were significantly reduced
4 days post-transduction while levels of miR-122 significantly
increased in the supernatant (Supplementary Fig. 4). Indeed,
HCV RNA levels in culture supernatant significantly increased
by day 7 and further increased at day 14 post-transfection
(Po0.05, t-test, Supplementary Fig. 4, right), indicating that miR-
122 may be secreted from HCV-infected B cells. Furthermore,
miR-122 levels were measured in immune cells isolated from
HCV patients. Consistent with in vitro results, circulating
miR-122 levels were significantly increased in HCV-infected
patients (Po0.05, t-test, Fig. 3f). The increased expression
of miR-122 in B cells was confirmed in memory B cells from
HCV patients (n¼ 9). The higher miR-122 levels in memory
B cells showed a positive correlation with higher cellular HCV
RNA levels (r¼ 0.67, Po0.05, t-test, Fig. 3g).
In order to determine if reduction of miR-122 levels had a
negative effect on HCV replication in B cells, an antagomir of
miR-122 was transfected into human memory B cells isolated
from HCV patients and examined for effect on cellular levels
of HCV RNA in B cells. These primary cells were incubated
ex vivo to allow HCV replication. Interestingly, transfection of
miR-122 antagomir into patients’ memory B cells significantly
lowered HCV replication (Po0.05, t-test; Fig. 3h).
Transfer of miR-122 via exosomes was tested in vitro for effect
on HCV replication. Exosomes derived from HCV patients
or healthy individuals were added to the supernatant of
HCV-infected Raji cells and examined for effect on HCV
replication. Addition of exosomes containing high miR-122
levels from HCV patients indeed enhanced HCV replication
(14-fold increase of HCV RNA) in Raji cells (Fig. 3i). These
results indicated that miR-122 promotes HCV replication in
B lymphocytes.
CLDN1/OCLN can rescue hepatotropic HCV infection.
We next studied the cellular basis for the lymphotropism
of the SB virus by focusing on the role of CLDN1 and OCLN,
which have been shown to be the co-receptors for HCV infection
of Huh7.5.1 cells13,16. CLDN1 and OCLN are normally expressed
at very low or undetectable levels in Raji cells (Fig. 4a) (ref. 56).
To test whether overexpression of either CLDN1 or OCLN could
render Raji cells more susceptible to infection by hepatotropic
JFH-1, we overexpressed CLDN1 or OCLN in Raji cells. As
shown in Fig. 4b, overexpression of CLDN1 or OCLN in Raji cells
resulted in only a marginal increase of viral entry and not to the
extent observed for SB (E1-E2). By comparison, HCVpp bearing
E1-E2 of Con1 or JFH-1 could not infect Raji cells. It is not clear
if lower infectivity was due to inability to adsorb and enter cells or
due to lower efficiency of viral gene expression and replication.
To test if HCV cell entry required both OCLN and CLDN1
co-receptors, both OCLN and CLDN1 were simultaneously
transfected into Raji cells prior to challenge with HCVpp-JFH1.
The extent of successful HCV intracellular entry was assessed by
luciferase assay (Fig. 4c). As four human co-receptors (OCLN,
CLDN1, CD81 and SR-BI) are critical for HCV entry into
hepatocytes, the effect of OCLN and CLDN1 overexpression was
examined in Raji cells, which normally lack their expression.
Interestingly, Raji cells expressing both OCLN and CLDN1 were
found to promote entry of hepatotropic JFH1 HCV (Fig. 4c),
confirming that viral entry required co-expression of both OCLN
and CLDN1. The intrinsic ability of HCVpp-SB to infect Raji
cells, but not HCVpp-JFH1, in the absence of OCLN and CLDN1,
to infect Raji cells gives further support to our contention that the
SB strain is lymphotropic (while Huh7 cells express all four
receptors CLDN1, OCLN, CD81 and SR-BI).
On the other hand, CLDN1, OCLN, SR-BI or CD81 knock-
down in Huh7.5.1 cells potently inhibited the infection by
HCVpp-JFH-1 (Fig. 4d,e), confirming the previous report
describing essential roles of four co-receptors CLDN1, OCLN,
CD81 and SR-BI for virus entry into hepatocytes12,13,16,57. In
contrast, while the knockdown of CD81 or SR-BI inhibited
HCVpp-SB infectivity in Raji cells, knockdown of CLDN1 or
OCLN did not exhibit this inhibition. The results of Fig. 4d,e
indicated that, in contrast to JFH1, SB strain entry is a CD81- and
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SR-BI-dependent but CLDN1- and OCLN-independent pathway
for infection of B cells.
B7.2 is a co-receptor for lymphotropic HCV of B cells. Inability
of SB to infect hepatocytes indicated that some other cell surface
co-receptor proteins were needed. In an effort to identify the
potential novel co-receptor specific for lymphotropic HCV
infection, we performed a lentivirus-based screen of a cDNA
library, derived from the highly HCV-permissive B lymphoma
cell lines Raji and Daudi. This screen was designed for identifi-
cation of genes that rendered the non-permissive CD81þ
SR-BIþ HEK293T cell line susceptible to infection by HIV-luc
reporter vector pseudotyped with HCVgp (HCVpp) (Fig. 5a).
The result of this functional screen identified ten co-receptor
candidate genes (Supplementary Fig. 5), which were tested in
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shRNA-transduced Raji cells for HCVpp entry. As a result of
this screen and confirmatory knockdown experiments, B7.2
(or CD86) was identified as a potential entry factor. B7.2 did not
affect HEK293T susceptibility to HIV-luc particles either lacking
envelope proteins (Envpp) or pseudotyped with unrelated
vesicular stomatitis virus G protein (VSV-Gp); these served as
negative and positive infection controls, respectively. Accordingly,
HCVpp-E1-E2 (SB strain) infection of Raji cells was inhibited by
anti-B7.2 and anti-CD81/anti-SR-BI (known HCV co-receptors),
but not by a control isotype antibody (Fig. 5b).
To further determine if B7.2 is required for HCV-SB infection
of B cells, Raji cells were infected with lentiviruses expressing
shRNAs targeting different regions of B7.2. The B7.2 knockdown
results showed that HCVpp-SB infection was markedly reduced
in B7.2-silenced cells as compared to cells treated with a
scrambled shRNA (Fig. 5c). When using distinct shRNAs of
variable potency against B7.2, HCVpp infectivity was inversely
correlated to the degree of silencing (Fig. 5d). By comparison,
B7.2 knockdown in Huh7.5.1 cells did not inhibit HCVpp (JFH1)
infection (Supplementary Fig. 5A). Next, to determine if the entry
step of virus infection required B7.2, synchronized infections were
performed on Raji or Huh7.5.1 cells in the presence of blocking
antibodies (Fig. 5e). The kinetics of inhibition by anti-B7.2
antibody was significantly slower than that for anti-CD81
antibody, with half-maximal inhibition observed at 128min
post-temperature shift while the half-maximal inhibition time of
anti-CD81 was 32min. In contrast, anti-B7.2 antibody did not
inhibit HCVpp (JFH1) infection of Huh7.5.1 cells. The time
course of inhibition was similar to that observed for the Claudin-
1 antibody16. Thus, these results were consistent with the
interpretation that anti-B7.2 antibody inhibited a step after
virus binding.
We next examined which domains of B7.2 are responsible for
interaction with SB envelope proteins. While exogenous B7.2
allowed HCVpp to infect B7.2-silenced Raji cells, neither B7.1 nor
ICAM supported HCVpp infection (Fig. 5f). Furthermore
replacement of the IgV domain of B7.2 with that from B7.1
abrogated the HCVpp infection of B7.2-silenced Raji cells
(Fig. 5f). The importance of the B7.2 cytoplasmic domain was
underscored since replacement of this domain with that from
CD8 also resulted in the loss of HCVpp infectivity. To test if a
direct interaction occurred between E2 and B7.2, we performed
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coimmunoprecipitation with anti-B7.2, followed by immunoblot
for E2 proteins and showed an interaction between B7.2 and
HCV E2 proteins (Fig. 6a and Supplementary Fig. 9). Reciprocal
immunochemical analysis further confirmed E2-B7.2 interactions
(Supplementary Fig. 5C and Supplementary Fig. 9). These results
indicated that B7.2 is a co-receptor for HCV-SB infection of Raji
cells.
We further examined whether the level of B7.2 expression in B
cells of hepatitis C patients correlated with the extent of HCV
infection. Naı¨ve B cells (CD19þCD27 ) were found to have low
levels of B7.2 expression, while memory B cells (CD19þCD27þ )
showed higher expression levels (Fig. 6b), in agreement with
previous reports58. Interestingly, memory B cells in HCV patient-
derived PBMCs expressed significantly lower levels of surface
B7.2 when compared to those in HCV ( ) individuals (Fig. 6c).
Significantly, HCV RNA levels were two logs higher in memory
B cells than in naı¨ve B cells isolated from HCV patients, which is
correlated with increased protein levels of B7.2 (Fig. 6d). These
findings were confirmed by examination of 18 different hepatitis
C patients (Fig. 6e). Lower surface B7.2 levels were correlated
with lower cellular HCV RNA levels (Supplementary Fig. 5D).
Activation of B cells (CD40Lþ IL-4 treatment) is known to
promote surface B7.2 expression in naı¨ve B cells59. Interestingly,
activation of B cells resulted in higher levels of cellular HCV RNA
8 days post-HCV (SB/JFH1) infection (Supplementary Fig. 5E).
Anti-CD81, anti-SR-BI or anti-E2 neutralizing antibody
treatment blocked HCV infection in sh-RIGI-Raji cells
(Supplementary Fig. 5F). B7.2 expression in B and T cells and
dendritic cells was confirmed by immunoblot (Supplementary
Fig. 5G). These results indicated that CD81, SR-BI and E2 are
involved in critical steps for lymphotropic HCV entry process
into B cells. This conclusion is limited to B cells, but not in T-cell
Gag
CMV VSV Gp
CMV cDNA library
Pur-HCVpp
r
Puromycin Test for 
HCVpp entry
cDNA
Luc
Luc
Luc
Luc-HCVpp
Luc-VSVpp
Luc-Env (–)
0
20
40
60
80
100
120
Synchronized 
infection
Blocking of 
CD81 or B7.2
α-CD81 or 
α-B7.2 Ab
Raji and Huh7.5.1
?
Luciferase
expression
Luciferase
assay
Blocking of entry?
4°C 2 hr 37°C 37°C
Virion
binding
α-CD81 blocking antibody
Time after α-B7.2 
antibody addition (min)
(Half-maximal inhibition: 128 min) 
Time after α-CD81 
antibody addition (min)
(Half-maximal inhibition: 32 min) 
HCVpp (SB) in Raji
HCVpp (JFH1) in Huh7.5.1
Isotype IgG in Raji
None in Raji
0 030 60 12
0
18
0
24
0
30
00
20
40
60
80
100
120
−
18
0
−
12
0 30 60 12
0
18
0
24
0
30
0
−
18
0
−
12
0
H
CV
pp
 e
nt
ry
 (%
)
α-B7.2 blocking antibody
Raji
Sc
ra
m
bl
ed
sh
-C
D8
1
 
76
45
 
11
09
3
76
47
sh-B7.2
0
25
50
75
100
125
150
N
or
m
al
iz
ed
 R
LU
HCVpp (SB)
MLVpp
*
*
*
*
100
1,000
10,000
100,000
Lu
ci
fe
ra
se
 a
ct
ivi
ty
(R
LU
)
SB
 E
1E
2
JF
H1
 E
1E
2
Co
n1
 E
1E
2
VS
V 
gp
N
o 
en
v
Selected HEK293T cells
with B cell cDNA library
SB
 E
1E
2 
+ 
α
-
-
B7
.2
SB
 E
1E
2 
+ 
Is
ot
yp
e
SB
 E
1E
2 
+ 
α
-
SR
-B
I
SB
 E
1E
2 
+ 
α
-
CD
81
*
* *
Raji
P = 0.042
r = −0.79
R
el
at
iv
e 
in
fe
ct
ivi
ty
 (%
)
0
0
20
40
60
80
100
120
150231 131
Signal 
peptide
Extracellular 
domain TM
IgC
IgC
IgV
IgV
Cytoplasmic
domain 
IgCIgV CD8
CD8
ICAM-1
ICAM-1
B7.2
IgCIgVB7.2/B7.1/B7.2
IgCIgVB7.1/B7.2/B7.1
B7.2/CD8
IgCIgVB7.1
ICAM-1
ICAM-1/CD8
IgC
IgV
B7.1
Normalized RLU
HCVpp
VSV-Gp225 269 329
B7.2
0 10 100 1000
Purr
Pol
20 40 60 80 100
Reduction in B7.2+
cell population (%)
a b c d
e f
Figure 5 | Co-stimulatory molecule B7.2/CD86 is identified as a co-receptor for lymphotropic HCV infection in B lymphocytes. (a) Expression cloning
of lymphotropic HCV receptor. HEK293T cells were transfected with B-cell cDNA library and selected with functional screening using HCVpp(SB) as the
ligand and puromycin or other selection antibiotic. To recover B-cell cDNAs in selected (surviving) colonies, DNA was isolated from these selected
HEK293T cells and amplified by PCR with specific primers to identify the inserted cDNA library sequence. (b) The blocking effects of anti-B7.2 and
anti-CD81 on HCVpp(SB) infection (*Po0.05, t-test, n¼ 3). Error bars represent s.d. (c) B7.2 silencing inhibited HCVpp-SB entry into Raji cells. The
HCVpp entry experiment was performed in triplicate (n¼ 3). Error bars represent s.d. (d) Correlation plot between B7.2 levels and relative infectivity.
(e) Time course of the blocking effects of anti-B7.2 and anti-CD81 on HCVpp(SB) infection. Synchronized infections were performed on Raji or Huh7.5.1
cells. Values (percent entry) are relative to the signal seen when the antibody was added at 4 h post temperature shift. Cellular HCV RNA levels were
detected in Raji cell cultures treated with isotype-matched or anti-B7.2 or anti-CD81 antibody. Fits of t¼0 and later data points represent a one-phase
exponential association and sigmoidal dose-response (variable slope) for anti-B7.2 (50mgml 1) or anti-CD81 (50 mgml 1) antibody (mean of n¼ 3; error
bars, s.d.). (f) Both B7.2 IgV and cytoplasmic regions are required for efficient HCV entry. The Raji cells (B7.2low) transduced with lentivirus expressing
sh-B7.2 were electroporated with GFP-B7.2 (B7.2), GFP-B7.2/CD8 (B7.2/CD8), GFP-ICAM-1 (ICAM-1) or GFP-ICAM-1/CD8 (ICAM-1/CD8) vectors. HCV
entry levels were assessed for luciferase activities at 72 h after HCVpp challenge of transfected cells (n¼ 3). Error bars represent s.d.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13882
8 NATURE COMMUNICATIONS | 8:13882 | DOI: 10.1038/ncomms13882 | www.nature.com/naturecommunications
lines since SR-B1 involvement is known for HCV infection of
primary T cells. Interestingly, primary T lymphocytes do not
display detectable levels of SR-B1 protein, although T-cell lines
do60.
Characterization of HCV particles produced from SB strain.
The concentrated virus particles had a density of 1.13 gml 1 in
sucrose (Fig. 7a), which is in agreement with previous report
(1.12 gml 1) of HCV virions isolated from the human T-
and B-cell lines HPBMa10-2 and Daudi25, but slightly less than
that of HCV virions isolated from hepatocytes (ca. 1.15 gml 1)
(refs 41,61). To further characterize SB viral RNA, SB-transfected
cells were metabolically labelled with [3H]uridine in the presence
of actinomycin D. The viral particles produced from transfected
cells were concentrated from the culture supernatant
and separated by sucrose gradient sedimentation. A specific
3H-uridine-labelled peak, which was resistant to protease
treatment, was detected in the culture supernatant of Raji cells
(Fig. 7a). RNA isolated from this material yielded a major RNA
species of approximately 9.7 kb and a minor RNA species. The
latter could be defective interfering RNA (DI RNA), although
further work will be needed to ascertain this (Fig. 7b).
Electron microscopy demonstrated that the particles were
approximately 50-60 nm in diameter and possessed an envelope
that was immunoreactive with anti-E2 antibodies (Fig. 7c).
Furthermore, 35S-amino acid-labelled virus particles at the peak
fraction contained several viral proteins, corresponding to core,
E1, and E2, all of which are associated with HCV particles
(Supplementary Fig. 6A). The putative identities of 35S-labelled
core and envelope protein E2 were confirmed by immunopreci-
pitation, followed by autoradiography (Supplementary Fig. 6B).
It was notable that the virion contained relatively more envelope
proteins than core proteins. Treatment with NP-40 disrupted the
virus particles, consistent with its identity as an enveloped virion
(Supplementary Fig. 6C). The sum of these analyses confirmed
that the viral particles produced from the SB-transfected cells in
this system had outer cell surface markers consistent with
authentic HCV particles.
To determine whether the viral particles released
were infectious, we harvested the culture media from SB
RNA-transfected Raji cells (sh-RIGI-Raji) which in turn was
used to infect naı¨ve Raji cells. The HCV RNA isolated from
infected cells was then analysed 8 days later. UV irradiation of
virus-containing media prior to infection prevented viral RNA
production (Fig. 7d). Also, pretreatment of the transfected cells
with IFN-a or -g, which inhibits viral RNA replication but not
viral attachment, lowered HCV RNA levels in a dose-dependent
manner (Fig. 7d). Finally, treatment with Telaprevir62, an NS3
(viral protease) inhibitor, or 20-modified nucleosides as inhibitors
of HCV replication (20-C-methy adenosine) also reduced HCV
RNA levels in a dose-dependent manner (Fig. 7e).
Active viral RNA replication was also confirmed by
the detection of ( ) strand RNA in SB-transfected but not
HCV (–) individuals
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Figure 6 | Envelope protein E2 of HCV SB strain interacts with B7.2 protein in shRIGI-Raji cells and surface B7.2 is reduced in memory B cells of HCV
patients. (a) Envelope protein E2 of HCV SB strain interacted with B7.2 protein in shRIGI-Raji cells. Arrows indicate bands of HCV E2. (b) B cells
from healthy individuals (upper panel) and HCV patients (lower panel) were sorted by flow cytometry into CD19þCD27- naı¨ve B cells or CD19þCD27þ
memory B cells. The former expressed a low level of B7.2, whereas the latter expressed a high level of B7.2. (c) Surface B7.2 expression is reduced
in human memory B cells in HCV patients. Human patient B cells were sorted into two fractions, naı¨ve B cells (CD19þ /CD27 ) and memory B
(CD19þ /CD27þ ), and used for RNA isolation. (d,e) Memory B cells were infected with HCV. Human memory B cells showed higher levels of HCV RNA
in clinical specimens (*Po0.05, t-test, n¼ 3). Error bars represent s.d. Analysis of HCV RNA in B cells, T cells, monocytes and dendritic cells.
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JFH1-transfected sh-RIGI-Raji cells (Supplementary Fig. 6D).
Addition of anti-E2 neutralizing antibody prevented ( ) strand
RNA synthesis whereas control, non-specific isotype antibody
treatment had no effect on HCV replication (Supplementary
Fig. 6D, Lower panel). A quantitative estimate of (þ ) and ( )
strand HCV RNA synthesis showed the former was tenfold
higher in abundance than ( ) genomic RNA. These results
clearly demonstrated that active SB HCV RNA replicates in B
cells.
By immunofluorescence studies, we also showed that NS3-
positive cells could be detected in lymphotropic SB-transfected
Raji cells, but not in Huh7.5.1 cells. In contrast, NS3 was detected
in hepatotropic JFH-1-transfected Huh7.5.1 cells, but not Raji
cells (Fig. 7f). Transfection of replication incompetent strain
SB/JFH1 (GND) led to significantly lower levels of NS3 staining at
days 7 and 10 post-transfection (Fig. 7g). As a specificity control,
SB chimera containing NS5B GND mutations, which cannot
replicate in Raji cells (Construct G), did not yield any HCV RNA.
These results indicated that the RNA signal was indeed due to
viral infection and replication and not due to trapping of viral
particles on the outer cell surface. This finding was confirmed by
immunoblot (Supplementary Fig. 6E). Taken together, these
results demonstrated that HCV SB preferentially infects,
replicates and produces infectious virions in sh-RIGI-Raji cells,
whereas JFH-1 preferentially infects and replicates in Huh7.5.1
cells.
Persistent HCV infection of PBMC in a humanized mouse model.
We extended our study of the lymphotropic properties of
HCV-SB in vivo by using humanized mice. For this purpose
we generated mice with stably engrafted human CD34þ
hematopoietic progenitor cells into an immune-compromised
background line [Rag2 / ;Il2rg / (RG)-hu HSC mice].
Analysis of these animals (RG-hu HSC mice) following engraft-
ment indicated that 6–37% of immune cells were positive for
CD45þ of human origin that was maintained through 10 weeks
post-engraftment. After human peripheral blood leukocytes
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were detected at 16 weeks post-engraftment, the mice were
intravenously injected with either cell culture-derived HCV-SB
virus, HCV-JFH1 virus or a chimeric SB/JFH1 virus, the latter
of which contains the SB 50-UTR-NS2 genes of the JFH1 genomic
backbone (construct F). The HCV RNA levels in the PBMC of
these mice were then analysed by RT-PCR at different time
points after infection. As shown in Table 1, five of the six mice
infected with either SB or SB-JFH1 chimeric virus tested positive
for HCV RNA at 4 weeks post-inoculation; four of these six
mice remained HCV RNA positive for more than 10 weeks after
Table 1 | HCV infection analysis on immunocompromised mice transplanted with human hematopoietic stem cells (HSCs).
Viral inoculum* Humanized mice inoculated (n) HCV(þ ) mice at week 4w HCV(þ ) mice at week 10w HLA positivityz
Culture supernatant
SB 3 2 2 þ (26)
SB/JFH1 3 3 2 þ (31)
SB/JFH1þ Vehicle 3 3 3 þ (27)
SB/JFH1þTelaprevir 3 1 1 þ (29)
SB/JFH1þ Isotype Ab 3 3 3 þ (26)
SB/JFH1þ a-B7.2 3 1 1 þ (32)
JFH1 3 0 0 þ (34)
SB GND 3 0 0 þ (33)
SB/JFH1 3 0 0 þ (35)
JFH1 GND 3 0 0 þ (29)
Human subjects
P326152 3 0 0 þ (28)
P213654 3 0 0 þ (18)
P297865 3 0 0 þ (33)
P375648 3 0 0 þ (14)
P259643 3 0 0 þ (17)
P203524 3 2 0 þ (33)
P259804 3 2 0 þ (15)
P895462 2 2 2 þ (14)
P256137 3 1 2 þ (36)
P965701 3 2 0 þ (37)
P458612 3 2 0 þ (6)
P325164 3 2 1 þ (19)
P221450 3 0 0 þ (18)
P120354 3 0 0 þ (28)
*Viral inocula were obtained from nine different chronic HCV patients (coded) or from cell culture-derived HCV (that is, SB, SB/JFH1 chimera and JFH1).
wHCV positivity was determined by RT-PCR for HCV positive-strand RNA.
zHLA DNA was determined by FACS using antibody that is specific to human HLA.
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virus injection. HCV RNA was detected in PBMCs of these mice
(up to 2.7 105 particlesml 1: Fig. 8a). In contrast, mice
injected with JFH1 virus or the replication-incompetent strains
(GND mutant) of SB or JFH1 strains were negative for HCV
RNA.
We infected humanized mice with sera from 14 human
subjects, nine of whom tested positive for HCV. None of the
HCV-negative sera led to infection in these mice (Table 1). In
contrast, 13 of 24 mice inoculated with the HCV-positive sera
tested positive for HCV RNA at week 4, of which five mice
remained positive up to week 10. Injection of anti-B7.2 antibody
reduced both internal and cell surface associated HCV RNA levels
(Fig. 8a). Human PBMC from the infected Rag2 / ;Il2rg /
(RG) mice were further sorted into T and B lymphocytes,
monocytes, and dendritic cells and examined separately
for cellular HCV RNA. As shown in Fig. 8b, the HCV RNA
was preferentially detected in memory B cells. HCV RNA
was also detected in CD4þ and CD8þ T cells in humanized
mice (Fig. 8b). These results indicated that HCV was capable
of persistently infecting human B cells in a humanized mouse
model.
HCV binding downregulates B7.2 and inhibits Ig production.
As CD27þ memory B cells in HCV patients are anergic
(exhausted) B cells63,64, the functions of memory B cells infected
with HCV particles were examined accordingly. To determine if
HCV-infected CD27þ B cells had attenuated signalling upon
BCR ligation, Ca2þ mobilization was measured after
immunoglobulin (Ig)M stimulation with anti-human IgM. The
HCV-infected CD27þ B cells had diminished Ca2þ
mobilization (Fig. 9a), indicating that HCV-infected CD27þ
B cells are anergic to BCR-mediated stimulation. To test if
HCV-infected cells were prone to apoptosis, HCV-infected
primary memory B cells isolated from patients were stimulated
with CD40Lþ IL2þ IL-10 or vehicle control ex vivo
(Supplementary Fig. 9A). Treated memory B cells were stained
with annexin V (to measure apoptosis) and anti-CD27. After
incubation with vehicle control or CD40Lþ IL2þ IL-10
treatment, the percentage of annexin Vþ cells was higher in
the CD40Lþ IL4-stimulated HCV-infected B-cell subset than
that of UV-irradiated supernatant-treated cells (Supplementary
Fig. 9A). As CD40L stimulation transactivates pro-apoptotic
molecule Bax (ref. 65), Bax mRNA levels were also examined.
The treatment was found to induce BAX after cross-linking B7.2
on HCV-infected memory B cells (Supplementary Fig. 9A, right).
These data suggested that, in the absence of survival signals,
HCV-infected CD27þB cells were prone to apoptosis.
B7.2 is a costimulatory molecule that interacts with CD28
and CTLA-4 on T cells. In addition, B7.2 has a cytoplasmic
tail that transduces signals in antigen-presenting cells66,67. B7.2
stimulation results in the phosphorylation of phospholipase
Cg2 (PLCg2) and protein kinase C ab (PKCa/b), leading to
activation of transcription factor Oct-2 and eventual increased
IgG1 transcription and protein production68. Since binding of the
HCV E2 protein to CD81 can perturb the biological activities of
CD81 (ref. 69), we tested if the binding of HCV E2 to B7.2 also
affected B7.2 and its signalling pathways. To determine whether
HCVpp-SB infection reduced CD28/Fc-mediated activation of
PLCg2 and PKCa/b, we analysed the activation of PLCg2 and
PKCa/b. As shown in Supplementary Fig. 9B, CD28/Fc-mediated
phosphorylation of PLCg2 (Tyr1217) and PKCa/b (Thr638/641)
was reduced in HCVpp-infected memory B cells.
To test if the observed effects on signalling were due to
the E2–B7.2 interaction, we used purified recombinant E2
(SB strain) purified from Baculovirus expression system instead
of HCVpp-SB. To test if E2 (SB strain) binds to B7.2, His-tagged
E2 (without the transmembrane domain) from SB strain
(genotype 2b) and H77 strain (genotype 1a) were expressed in
the baculovirus expression system and partially purified
(Supplementary Fig. 7A). The intracellular E2 was detected in
both monomeric and aggregated forms (Supplementary Fig. 7B).
Immunoblot analysis confirmed expression of HCV E2 protein
(Supplementary Fig. 7C). The partially purified E2 was used for
in vitro binding to various cell lines as determined by flow
cytometry. The results showed that E2 from the SB strain bound
to Raji cells very efficiently. E2 from the genotype 2a JFH1 strain
does not bind to HepG2 cells (Supplementary Fig. 7D). The
binding strengths of E2 from SB and JFH1 strains were further
compared by using different amounts of E2 (normalized using an
anti-His6 antibody). E2 did not bind to HepG2 cells, which is
among the few human cell lines that do not express CD81 or
B7.2. In contrast, E2 bound to the B7.2-overexpressing HepG2
cells efficiently (Supplementary Fig. 7D). The binding was
partially blocked by a B7.2-specific antibody but not by an
isotype-matched control antibody (Supplementary Fig. 7D). As
shown in Supplementary Fig. 7E, E2 of the SB strain bound more
than that of the H77 strain at every protein concentration used.
These results indicated that recombinant E2 (SB lymphotropic
strain), but not E2 (H77 hepatotropic strain), bound to B cells in a
B7.2-dependent manner.
Furthermore, to rule out that the observed effects were
not a consequence of CD81 engagement by E2-SB, endogenous
CD81 was knocked out by CRISPR and replaced with exogenous
full-length CD81 or extracellular-domain-truncated CD81
expression vectors. CD81 overexpression partially restored
immunoglobulin production in CRISPR-mediated CD81 knock-
out cells (Supplementary Fig. 8A). To further test if another
co-receptor SR-BI stimulated immunoglobulin production,
SR-BI was knocked out by CRISPR and replaced with transfected
full-length SR-BI or intracellular-domain-truncated mutant of
SR-BI and examined for immunoglobulin production. Both
C-terminus truncation mutant and full-length SR-BI showed no
effect on IgM production in the CRISPR SR-BI knockout cells
expressing C-terminus truncation mutant of SR-BI or full-length
SR-BI (Supplementary Fig. 8B). B2.7 restoration promoted IgM
production while B7.2/CD8 chimera, which lacks the signal
transduction domain, failed to restore the IgM production
(Supplementary Fig. 8C, left). These results indicated that
HCV E2(SB)-mediated downregulation of B7.2 reduced
CD28/Fc-mediated signalling pathways.
HCV-infected B cells do not differentiate into plasmablasts.
To test whether binding of HCV to B7.2 inhibited B7.2-induced
signalling pathways, resting B cells were purified from human
PBMC for challenge with HCVpp-SB. As B7.2 signalling
promotes the IgM production, supernatants were collected on day
6 following the administration of CD40Lþ IL-2þ IL-10
and assayed by enzyme-linked immunosorbent assay
(IgM ELISPOT assay) for IgM production from these cells.
Memory B cells cultured with medium alone or with control
antibody did not induce antibody secretion. As illustrated in
Fig. 9b, memory CD27þ B cells were infected with HCVpp and
stimulated with CD40L, IL-2 and IL-10 for 6 days, which
differentiated B cells into antibody-secreting cells. Similarly,
treatment with CD28/Fc fusion protein induces B7.2 signalling
and activates Ig production pathways68. The pseudotyped
MLV viral particle, which does not bind to B7.2 but infects B
cells, did not affect CD28-mediated IgM production (Fig. 9b). We
observed that the HCVpp-infected CD27þ B cells were less
efficient at differentiating into IgM-secreting plasmablasts
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Figure 9 | HCV infection impairs antigen recall responses in memory B cell. (a) HCV-infected CD27þ B cells, compared to uninfected CD27þ B cells,
have attenuated Ca2þ responses after BCR cross-linking. B cells from healthy donor were loaded with Indo-1-AM, stained with anti-CD27 and warmed to
37 C. After establishing a baseline for 30 s, cells were stimulated with 10mgml 1 goat F(ab0)2 anti-human IgM. Kinetic graphs represent ratios of bound/
unbound Indo-1 AM over time for CD27þ B-cell populations. Arrows indicate addition time of F(ab0)2a–human IgM (*Po0.05, t-test, n¼ 3). Error bars
represent s.d. (b) Signals by anti-B7.2 Ab induce the production of IgM by memory B cells. Memory B cells (5 103 cells per well) were cultured with
different concentrations of anti-B7.2 (0.5mgml 1); after 5 days, supernatants from control and experimental wells were collected and IgM levels were
measured. Data are presented as the fold-increase above memory B cells activated with a CD40Lþ IL-2þ IL-10, and a species- and isotype-matched
control Ab (*Po0.05, t-test, n¼ 3). Error bars represent s.d. (c) Similar assays were performed using HCVcc as described with HCVpp above (*Po0.05,
t-test, n¼ 3). Error bars represent s.d. (c, inset) Silencing effect of shRNA targeting B7.2 was confirmed by immunoblot. (d) A model of lymphotropic HCV
infection in memory B cells. B7.2 serves as one of the co-receptors for HCV-SB infection of B cells. B7.2 (CD86) mediates lymphotropism of HCV infectious
clone derived from HCV SB strain towards human memory B cells and its binding suppresses the cells’ function by downregulating surface expression of
B7.2. Evasion of antiviral responses (that is, RIGI), induction of miR-122, and another host factor targeting HCV 50-UTR are involved in stimulating HCV
replication in B cells. HCV-mediated downregulation of B7.2 impairs anti-viral immune memory, including reduction of antibody production and antigen
recall responses.
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following CD40L/IL-2/IL-10 stimulation (Fig. 9b, left).
This suggested differentiation to IgM-secreting plasmablasts
upon CD40L/IL-2/IL-10 stimulation was impaired in HCVpp-
infected memory B cells, compared to uninfected memory B-cells
(Fig. 9b, left). These results indicated that HCVpp-SB-mediated
downregulation of B7.2 reduced CD28/Fc-mediated signalling
pathways. Silencing B7.2 or PLCg2 significantly reduced IgM
production in HCV-infected memory B cells (Fig. 9b, right).
In contrast, HCVpp-JFH1, which does not bind to B7.2, did not
inhibit IgM production. To confirm the biological relevance of
the pseudotyped HCV particle study, similar results were also
obtained when we used the HCV-SB virus (Fig. 9c). Class switch
did not account for the decreased IgM in these subsets, as
we consistently detectedo140 ngml 1 of IgM in cell culture
supernatants. Taken together, these results indicated
that infection with both HCVcc and HCVpp increased
IgM production and by downregulation of B7.2, attenuated
CD28-mediated IgM production; thus virus infection enhanced
the differentiation of memory B cells into IgM-secreting
plasmablasts.
Discussion
In this study, we have established the genetic basis for
lymphotropism of HCV infection. A comprehensive set of data
indicated that B7.2 is a co-receptor for observed HCV SB strain
tropism towards memory B cells. Previous reports have also
indicated that some HCV strains can infect human T cells: the
H77 strain of HCV can infect and replicate in established T-cell
lines, such as Molt-4 and Jurkat cells, in long-term culture21.
Furthermore, transfection of SB strain RNA, but not JFH1, led to
its replication in Molt-4 cells70. Here we provide evidence
indicating that B7.2 is involved in HCV SB strain tropism
towards memory B cells (additional discussion is described in
Supplementary Note 1).
B7.2 belongs to the immunoglobulin superfamily, and is highly
expressed on memory B cells and germinal centre B cells71. Its
ligand includes CD28 and CTLA4 on the surface of T cells. B7.2
and B7.1 are expressed by antigen-presenting cells including
B cells. The result of ligation of B7.2 leads to the following:
B7.2-CD28 interaction co-stimulates T-cell activation and
enhances T-cell survival, B7.2-CTLA4 interaction inhibits T-cell
activation and leads to T-cell tolerance. The infection of B cells by
HCV likely causes significant alteration of these functions72.
Furthermore, expression of HCV viral proteins in B cells can
result in B-cell lymphoma in transgenic mice73. The expression
levels of B7.2 are not correlated with cellular HCV RNA levels in
certain primary cells, such as dendritic cells—which are known to
be associated with HCV74—indicating that other co-receptor(s)
may exist for lymphocyte infection (Supplementary Fig. 5G).
Indeed, CD5 expression is linked to HCV infection of
lymphocytes75. Another possibility is that inhibitors of HCV
infection, such as Ewi-2wint, a partner of CD81, may be
associated with this lymphotropism76. Other studies have
shown ApoE to be a tropism determinant in a late assembly
step and viral cell-to-cell transmission of HCV JFH1 strain77.
In conclusion, HCV tissue tropism is determined primarily by
the properties of viral envelope proteins and the 50-UTR, in
addition to the ability of HCV to evade antiviral responses
(Fig. 7f). The existence of lymphotropic HCV strains indicates
that lymphoid cell infection may be an important facet of HCV
infection in some patients. These studies on the genetic basis of
lymphotropism of HCV will open up an avenue for studying
extrahepatic infection of HCV in vivo and in vitro. The SB strain
may be representative of lymphotropic quasispecies that arise
from an HCV infection that is primarily hepatotropic.
Methods
Cells. Raji (Cat# CCL-86), HEK293T (Cat# CRL-3216) and HepG2
(Cat# HB-8065) cells were obtained from ATCC. HepG2 cells were transfected
with pCDNA3.1-CD81 or B7.2 expression plasmid, selected with G418
(0.5 mgml 1) and surviving cell colonies were picked after drug selection.
Individual cell clones were further isolated and characterized for CD81 expression
and E2 binding. To generate sh-RIGI-Raji cells, Raji cells were transduced by
multiple lentivirus expressing shRNAs against RIG-I and MDA5 (Open Biosys-
tems) and/or miR122. The culture media for Raji and sh-RIGI-Raji cells is RPMI
media 1640, GlutaMAX (Cat#61870-036, Life Technologies) containing 20% FBS
(Omega, Inc.). PBMC were isolated by Ficoll-Paque Plus (Amersham Biosciences)
density gradient centrifugation. Informed consent was obtained. Institutional
Review Board at University of Southern California approved the procedures.
PBMC were maintained in RPMI 1640 containing 10% FBS. Infection of cells,
generation of HCV pseudo-particles and generation of HCV clone ar described
in Supplementary Methods.
Vector. The Claudin-1 expression vector was a gift from Dr Weeraratna from
National Institute of Aging (NIA/NIH). WT B7.2, B7.2-CD8, ICAM-1/CD8 and
WT ICAM-1 expression vectors were previously described (gifts from Dr Jung,
USC) (ref. 78).
Sucrose density gradient analysis. The viral particles produced from the
transfected cells were concentrated from the culture supernatant and separated by
sucrose gradient sedimentation. Culture medium derived from sh-RIGI-Raji cells
was harvested for sucrose density gradient analysis 6 days after transfection of full-
length SB RNA. Collected culture medium was cleared by low speed centrifugation
at 670g for 10min, and passed through a filter with 0.45-mm pore size (Millipore).
Filtered culture medium was layered on a stepwise sucrose gradient (60 to 10%,
wt/vol) and centrifuged for 16 h in a SW41 rotor (Beckman) at 40,000 or
50,000 rpm (273,865g or 427,914g) at 4 C. After centrifugation, 8 or 16 fractions
were harvested from the bottoms of the tubes. Core protein concentration in each
fraction was determined by an immunoassay using 100 ml of the fraction. HCV
RNA titer was determined by RTD-PCR using RNA isolated from 100 ml of the
fraction. The 35S labelling was performed by standard procedures.
Lentivirus production. To generate RIGI or MDA5 shRNA or a miR-122 lenti-
virus, the transfer vector expressing miR-122 or shRNA targets sequence on the
RIG-I or MDA5 cDNA (RHS4531-NM_022168, RHS4430-98851910, RHS4430-
99158156, RHS4430-99161339: MDA5 so called DDX58, or RHS4531-NM_014314,
RHS4430-98910525, RHS4430-99294017, RHS4430-99619590: RIG-I so called
DDX58; Human GIPZ Lentiviral shRNAmir target gene set, Open Biosystems)
were co-transfected with pPAX2 and pVSV-Gp expression vector in HEK293T
cells.
Cell entry assay. Virus infection was carried out at 4 C (no endocytosis) and then
shifted to 37 C (active endocytosis). Antibody-treated and untreated cultures were
infected with HCVpp(SB) or HCVpp(JFH1) for 1 h at 4 C. Plates were then
brought to 37 C and assayed at indicated time points over a 300min time
course. Controls are normalized to the value for anti-CD81 added at 4 h.
Antibodies directed against CD81 (JS81) or B7.2 were added at various time points
after temperature was shifted to 37 C, and the infectivity was determined at 12
days after infection as previously described. The concentration of B7.2 and
CD81 we used in the experiments are both 50 mgml 1. Half-maximal inhibition
time of anti-B7.2 was 132min while half-maximal inhibition time of anti-CD81
was 44min.
Immunoprecipitation followed by immunoblot for B7.2. Full-length of B7.2,
B7.2/CD8, full-length of ICAM or ICAM/CD8 were overexpressed in 293T cells.
After 24 h, the expression level of B7.2 was determined by western blots. For
infection, the culture media was replaced with fresh media containing either SB
HCVpp or JFH1 HCVpp and incubated an additional 24 h. Cell lysates were used
for mmunoprecipitation with anti-B7.2, followed by immunoblot for B7.2 proteins
in 293T cells.
After incubation, the cells were harvested and lysed for immunoprecipitation.
B7.2 only interacted with HCV E2 after SB infection, but not JFH1 infection. These
data indicate that SB E2 protein, but not JFH1 E2 protein, directly interacted with
B7.2.
Electron microscopy. Raji cells were transfected with HCV RNA and cell-free
supernatant was harvested 96 h post transfection and concentrated via ultra-
centrifugation. Grids were washed on drops of PBS, fixed with 3% paraformalde-
hyde in PBS and blocked in a solution of 0.8% BSA, 1% cold water fish skin gelatin
(Sigma) and 20mM Glycine in PBS. Immunogold labelling was performed with an
antibody directed against E2 (CBH5) diluted 1:50 in blocking solution, and Protein
A coupled to 10 nm gold particles. After extensive washing with PBS and a quick
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rinse with distilled water, grids were stained with a solution consisting of 9 parts
2% Methyl Cellulose and 1 part 3% Uranyl acetate (both aqueous solutions).
Isolation of human B cell. To isolate human memory and naı¨ve B cells from
14 healthy individuals and 18 HCV patients, EasySep Human Memory
B Cell Isolation Kit and EasySep Human Naı¨ve B Cell Enrichment Kit
(STEMCELL Technologies, Co. Ltd, USA) were used, respectively according to
instruction manuals. IRB approval is obtained by University committee.
Exosome isolation is described in Supplementary Methods.
Immunoblot. Proteins were detected by designated antibodies as following:
MDA5 (D74E4, Rabbit mAb, Cell Signaling #5321S, 1:1,000), MDA5 (Santa Cruz,
sc-48031, 1:1,000), RIG-I rabbit Ab (Cell Signaling, #4520S, 1:1,000), RIG-I
(Santa Cruz, sc-48929, 1:1,000), B7-2 (BU63, sc-19617, Santa Cruz Biotechnology,
1:1,000), B7.2 (Santa Cruz, sc-28347, 1:1,000), Claudin-1 mAb (ZYMED, #37-4900,
1:2,000). HCV E2 was detected by CBH5 or CBH17 antibodies (kind gifts from
Prof. Steven Foung in Stanford University, Palo Alto, CA, USA, 1:1,000). The
phosphorylation of PLCg2 (Tyr1217: Cell Signaling cat#: 3871 T, 1:2,000) and
PKCa/b II (Thr638/641: Cell Signaling cat#: 9375 T, 1:2,000) were analysed using
antibodies directed against their respective phosphorylated forms. Total protein
levels were determined using antibodies not specific for the phosphorylated
forms of these proteins. Uncropped scans of western blots are provided in
Supplementary Fig. 10.
Co-receptor cloning by lentivirus B-cell cDNA library screen. To identify the
possible novel receptor specific for the infection of lymphotropic HCV, we per-
formed a lentivirus-based screen of a cDNA library, derived from the highly
HCV-permissive B lymphoma Raji cell lines, for genes that render the non-per-
missive CD81þ SR-BIþ HEK293T cell line infectable with HIV-1 particles
pseudo-typed with HCVgp (HCVpp). More details are described in Supplementary
Methods.
RNA synthesis. XbaI-digested constructs were treated with mung bean nuclease
(New England Biolabs) to remove 4 nucleotides and leave the correct 30 end of
the HCV cDNA. Digested plasmid DNAs were purified and used as templates for
RNA synthesis. The HCV RNA was synthesized in vitro using the MEGAscript
T7 kit (Ambion, Austin, TX, USA). Synthesized RNA was treated with DNaseI
(RQ1 RNase-free DNase, Promega) followed by acid phenol extraction to remove
any remaining template DNA.
Baculovirus expression and purification of HCV E2 proteins. E2 sequences
from a genotype 2b isolate (strain SB) and genotype 2a isolate (strain JFH1)
without the C-terminal transmembrane domains but containing a His6 tag at the
C termini were cloned into a transfer vector (pBlueBacHis2; Invitrogen, Carlsbad,
CA, USA). Expression of recombinant E2 proteins in insect cells (Sf9) was
performed as described in the Bac-N-Blue Baculovirus Expression System
(Invitrogen) and purified as previously described79. Briefly, insect Sf9 cells were
grown in Grace’s Insect medium supplemented with 10% FBS at 28 C. The bacmid
DNAs were transfected into Sf9 cells; the virus generated was amplified two more
times at a low multiplicity of infection before being used for infection of Sf9 cells
(at high multiplicity of infection). At 72 h post-infection, cells were lysed in 50mM
Tris-HCl (pH 8.5), 0.15 M NaCl, 0.1% Triton X-100 and protease inhibitor cocktail
(Roche, Basel, Switzerland) and then sonicated and centrifuged at 100,000g.
E2 were purified from the crude lysates by using HiTrap chelating columns
(Amersham Biosciences, Piscataway, NJ, USA) loaded with 0.1 M NiCl2 (ref. 80).
The extracts were diluted in 50mM sodium phosphate (pH 8), 300mM NaCl and
10% glycerol (buffer A) and bound to the column (flow rate: 0.5mlmin 1).
The column was washed sequentially with buffer A, buffer B (50mM sodium
phosphate [pH 6], 300mM NaCl, 10% glycerol) and buffer C (50mM sodium
phosphate [pH 8], 1 M NaCl, 10% glycerol). The proteins were eluted in buffer A
containing 200mM imidazole and buffer exchanged into phosphate-buffered saline
without Ca2þ and Mg2þ [PBS( )] plus 10% glycerol.
Statistical analysis. ANOVA analysis was used for multiple comparisons. For
correlation analysis, Pearson’s correlation test was performed in GraphPad Prism
software. For all other statistical analyses, the nonparametric Mann-Whitney
test or two-tailed t-test was employed. Values of Po0.05 were considered to be
statistically significant.
Data availability. The sequence of the HCV SB clone has been deposited in the
GenBank Nucleotide database with the accession code KM349851. The authors
declare that all other relevant data are available from the authors on request.
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